PARP1 and neoplasm: However, in this study, we wished to determine whether repetitive administration of a PARP-1 inhibitor (olaparib) prior to radiotherapy (i.e. strictly neoadjuvant, rather than concurrent, olaparib treatment) could improve tumour oxygenation prior to radiation treatment.